2023 World Conference on Lung Cancer (Posters)-EP11.03. Optimal Duration of Immune Checkpoint Inhbitors in Non-small Cell Lung Cancer: Less Is More?

EP11.03. Optimal Duration of Immune Checkpoint Inhbitors in Non-small Cell Lung Cancer: Less Is More? - PDF(Slides)

Pdf Summary

The use of immune-checkpoint inhibitors (ICIs) has significantly improved the overall survival of patients with non-small cell lung cancer (NSCLC) compared to traditional chemotherapy. While most clinical trials have set a two-year treatment duration as a cut-off point, it is not universally accepted in routine clinical practice. In this study, researchers aimed to describe the outcomes of NSCLC patients who were treated with ICIs for two years in their center.<br /><br />The study was conducted retrospectively, analyzing data from patients diagnosed with advanced NSCLC who received ICIs for at least two years. Out of the 303 patients who received ICI therapy, only 19 completed the full two years without disease progression. All of these patients received ICI monotherapy without combination with chemotherapy or other drugs.<br /><br />After discontinuing ICI therapy, 31.6% of patients experienced disease progression, with a median time to progression of 16.8 months. Among those who progressed, only 50% had achieved disease stabilization at six months, while 92.3% of patients without progression achieved partial response. Four patients died due to tumor progression, with a median time to death of 6.8 months since disease progression. Only one patient was re-treated with ICIs and showed tumor stabilization.<br /><br />The study suggests that most patients maintained their response after two years of ICI therapy, supporting the idea that two years may be an optimal duration for treatment. However, larger studies are needed to further investigate this and identify potential biomarkers that can help individualize treatment duration.<br /><br />In summary, this study provides insights into the outcomes of NSCLC patients who were treated with ICIs for two years. It suggests that longer-term survival can be achieved with two years of ICI therapy, but further research is necessary to validate these findings and develop personalized treatment protocols.

Asset Subtitle

Mariola Blanco Clemente

Meta Tag

Speaker Mariola Blanco Clemente

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

immune-checkpoint inhibitors

non-small cell lung cancer

NSCLC

chemotherapy

clinical trials

treatment duration

disease progression

ICI monotherapy

disease stabilization

tumor progression